NASS Responds to US Senate Finance Committee Report on Infuse

The recent investigation by the U.S. Senate Committee on Finance into the surgeon/industry relationships, scientific publishing and marketing of Medtronic’s bone morphogenic protein product InFuse was released earlier this week and confirms reports from the June 2011 issue of the North American Spine Society‘s The Spine Journal.

Advertisement

According to the report, the lead authors on the 13 original studies of InFuse received payments ranging from $1.7 million to $64 million and Medtronic’s marketing employees were co-authors and co-editors on the studies.

NASS strongly advocates that data published in scientific journals and shared at medical conferences is accurate, complete and transparent.

More Articles on Spine Surgery:

Spine Surgery QALY Gains $56,592 Over Medical Management for Spinal Stenosis

10 Most Important Qualities for Spine Surgeon Leaders Today

ISASS Joins Medical Societies Petition to Eliminate SGR

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

160 ambulatory leaders just ranked the EHR as the single system most overdue for AI reinvention

Tuesday, August 11
12:00 PM - 1:00 PM CDT

Presenter: Gautam Shah, MBA, FACHDM, NextGen Healthcare

Advertisement

Next Up in Spine

Advertisement

Comments are closed.